Mitchell Hourtienne - 18 Sep 2023 Form 3 Insider Report for Cepton, Inc.

Signature
/s/: Ming Qiu, Attorney-in-Fact for Mitchell Hourtienne
Issuer symbol
N/A
Transactions as of
18 Sep 2023
Net transactions value
$0
Form type
3
Filing time
19 Sep 2023, 17:00:51 UTC
Next filing
22 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CPTN Common Stock 100,000 18 Sep 2023 Direct F1
holding CPTN Common Stock 172,308 18 Sep 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CPTN Employee Stock Option (right to buy) 18 Sep 2023 Common Stock 9,185 $0.9700 Direct F3
holding CPTN Employee Stock Option (right to buy) 18 Sep 2023 Common Stock 39,347 $1.02 Direct F4
holding CPTN Performance Stock Units 18 Sep 2023 Common Stock 67,000 Direct F5
holding CPTN Employee Stock Option (right to buy) 18 Sep 2023 Common Stock 61,230 $1.26 Direct F6
holding CPTN Employee Stock Option (right to buy) 18 Sep 2023 Common Stock 244,922 $1.26 Direct F7
holding CPTN Employee Stock Option (right to buy) 18 Sep 2023 Common Stock 511 $0.6800 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 100,000 time-based restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock, that vest on May 20, 2024, subject to early termination and adjustments as provided in the applicable award agreement.
F2 Represents 172,308 RSUs, each of which represents a contingent right to receive one share of the Issuer's Common Stock, that vest in three equal installments on February 20, 2024, February 20, 2025 and February 20, 2026, in each case subject to early termination and adjustment as provided in the applicable award agreement.
F3 The stock options vested as to 25% of the total number of shares of Common Stock subject to the stock options on November 20, 2020. The remaining 75% of the total number of shares of Common Stock subject to the stock options vest thereafter in 36 substantially equal monthly installments.
F4 The stock options vested as to 25% of the total number of shares of Common Stock subject to the stock options on January 31, 2021. The remaining 75% of the total number of shares of Common Stock subject to the stock options vest thereafter in 36 substantially equal monthly installments.
F5 The Issuer awarded the Reporting Person 67,000 performance-based stock units ("PSUs"), each of which represents a contingent right to receive one share of the Issuer's Common Stock. The award will vest as to 36,000 of the PSUs if, at the close of regular trading for 20 trading days out of any period of 30 consecutive trading days, either (i) the Issuer's closing stock price exceeds $15.00 per share or (ii) the Issuer's market capitalization exceeds $2.1 billion; and will vest as to the remaining 31,000 PSUs if, at the close of regular trading for 20 trading days out of any period of 30 consecutive trading days, either (i) the Issuer's closing stock price exceeds $17.50 per share or (ii) the Issuer's market capitalization exceeds $2.5 billion, expiring on February 10, 2025 for each applicable tranche, and provided further that the vesting of each tranche is subject to the Reporting Person's continued employment with the Issuer through the day on which the applicable goal is achieved.
F6 The stock options vested as to 25% of the total number of shares of Common Stock subject to the stock options on November 23, 2021. The remaining 75% of the total number of shares of Common Stock subject to the stock options vest thereafter in 36 substantially equal monthly installments.
F7 The stock options vest monthly, starting on March 8, 2021, in 48 substantially equal monthly installments.
F8 The stock options are fully vested and exercisable.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney